drugset / Trial / NCT05371730
A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes
Phase 0
Unknown
15 enrolled
Nuwacell Biotechnologies Co., Ltd.
The First Affiliated Hospital of University of Science and Technology of China · collab
NaSingle-groupOpen-labelTreatment
Summary
A clinical study to Evaluate the Safety and Efficacy of NK cells in the treatment of Myelodysplastic Syndromes
Timeline
- Start
- 2022-05-30
- Primary completion
- 2025-05-30
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NCR300 | Unknown | — | Intravenous |